文献速递消化道肿瘤放疗胸部肿瘤放疗放疗物理与技术

序贯18F-FDG PET/CT代谢参数预测接受(放)化疗的食管癌患者总生存期

Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation.
PubMed 文献 · Radiat Oncol · 2019-02-19

本研究回顾性分析134例病理确诊的食管鳞癌患者,于治疗前及放疗40 Gy后行18F-FDG PET/CT,记录SUVmax、MTV、TLG及其变化百分比。单因素分析显示SUVmax2、MTV1、△MTV、TLG1、TLG2和△TLG与总生存期相关,多因素分析显示SUVmax2是独立于TNM分期和原发肿瘤长度的预后因素。

要点

  • 治疗前及放疗40 Gy时的序贯18F-FDG PET/CT代谢参数对食管鳞癌患者总生存期有预后价值。
  • SUVmax2、MTV1、△MTV、TLG1、TLG2和△TLG与总生存期相关。
  • SUVmax2是独立于TNM分期和原发肿瘤长度的总生存期预后因素。

核心结论

  • 序贯18F-FDG PET/CT代谢参数对食管癌患者总生存期具有重要预后价值。
  • 治疗前及放化疗期间的18F-FDG PET/CT扫描似乎有助于评估放化疗效果、指导临床决策并为患者提供个体化治疗。

研究设计与样本

  • 回顾性分析2009年7月至2013年10月在本院治疗的134例病理确诊的食管鳞癌患者。
  • 纳入标准为根治性放疗且具备治疗前和中期18F-FDG PET。
  • 于治疗前和放疗40 Gy后行18F-FDG PET/CT扫描,记录SUVmax、MTV、TLG及两次扫描间的变化百分比。

主要发现

  • 单因素生存分析显示SUVmax2、MTV1、△MTV、TLG1、TLG2和△TLG与总生存期相关。
  • 基于ROC曲线最大约登指数,SUVmax2<7.8、MTV1<10.5、△MTV<0.075、TLG1<59.8、TLG2<44.3和△TLG<0.27的患者倾向于生存更长。
  • 按上述参数分层,估计中位生存时间分别为27.9个月 vs 9.8个月、36.9个月 vs 11.3个月、41.6个月 vs 12个月、48.9个月 vs 14.3个月、32.6个月 vs 13.2个月和41.6个月 vs 14.5个月。
  • Cox多因素回归分析显示SUVmax2是独立于TNM分期和原发肿瘤长度的总生存期预后因素。

关键数值与推荐

  • SUVmax2<7.8、MTV1<10.5、△MTV<0.075、TLG1<59.8、TLG2<44.3和△TLG<0.27的患者中位生存时间更长。
  • 上述阈值基于ROC曲线最大约登指数确定。

临床怎么用

  • 原文结论认为治疗前及放化疗期间的18F-FDG PET/CT扫描似乎有助于评估放化疗效果、指导临床决策并提供个体化治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the prognostic value of metabolic parameters of pre-treatment and interim 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) for overall survival (OS) of esophageal cancer(EC) patients undergoing (chemo-) radiotherapy. METHODS: A retrospective analysis of 134 patients with pathology confirmed squamous cell EC treated between July 2009 and October 2013 in our hospital was performed. Inclusion criteria for this study were curative intended radiotherapy and availability of pre-treatment and interim 18F-FDG PET. 18F-FDG PET/CT scans were acquired before treatment and after 40 Gray (Gy) of radiotherapy. Maximum standard uptake value (SUVmax), metabolic tumor volume(MTV), total lesion glycolysis (TLG), and the percentual changes during both PET scans were recorded. The parameters were named as SUVmax1,MTV1,TLG1,SUVmax2,MTV2,TLG2,△SUVmax,△MTV and △TLG. The receiver operating characteristic curve (ROC) was used to analyze the relationship between metabolic parameters and OS, survival analysis was carried out by Kaplan-Meier and Cox regression analysis. RESULTS: Univariate survival analysis showed that SUVmax2、MTV1、△MTV、TLG1、TLG2 and △TLG were associated with OS. Based on the largest Youden index of ROC curves, patients with SUVmax2 < 7.8, MTV1 < 10.5, △MTV < 0.075, TLG1 < 59.8, TLG2 < 44.3 and △TLG < 0.27 tended to live longer. Stratified for these parameters, the estimated median survival time were 27.9 months (m) vs 9.8 m, 36.9 m vs 11.3 m, 41.6 m vs 12 m, 48.9 m vs 14.3 m, 32.6 m vs 13.2 m, and 41.6 m vs 14.5 m. Cox multi-factor regression analyses revealed SUVmax2 as an independent prognostic factor for OS complementary to TNM staging and the length of primary tumor. CONCLUSIONS: Sequential 18F-FDG PET/CT metabolic parameters bear important prognostic value for OS of EC patients. 18F-FDG PET/CT scan before treatment and during chemoradiotherapy seems helpful to evaluate the effect of chemoradiotherapy, guide clinical decisions and provide patients with personalized treatment.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Li Y, Zschaeck S, Lin Q, et al. Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation. Radiat Oncol. 2019. PMID: 30782182. doi:10.1186/s13014-019-1236-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。